Drug Type Small molecule drug |
Synonyms Acrel, Actonel Combi, Atelvia + [21] |
Target |
Mechanism FDPS inhibitors(Farnesyl diphosphate synthase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date |
RegulationOrphan Drug (US) |
Molecular FormulaC7H11NNaO7P2 |
InChIKeyJAROYDNJQWMRAM-UHFFFAOYSA-N |
CAS Registry115436-72-1 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Risedronate Sodium |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Osteoporosis | AU | 14 Aug 2000 | |
Glucocorticoid-induced osteoporosis | US | 27 Mar 1998 | |
Osteitis Deformans | US | 27 Mar 1998 | |
Osteoporosis, Postmenopausal | US | 27 Mar 1998 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Prostatic Cancer | Phase 3 | CA | 01 Jan 2007 | |
Bone Diseases, Metabolic | Phase 3 | CA | 01 Apr 2006 | |
Bone Diseases, Metabolic | Phase 3 | DE | 01 Apr 2006 | |
Bone Diseases, Metabolic | Phase 3 | CH | 01 Apr 2006 | |
Osteogenesis Imperfecta | Phase 3 | US | 01 Nov 2004 | |
Osteogenesis Imperfecta | Phase 3 | AU | 01 Nov 2004 | |
Osteogenesis Imperfecta | Phase 3 | BE | 01 Nov 2004 | |
Osteogenesis Imperfecta | Phase 3 | CL | 01 Nov 2004 | |
Osteogenesis Imperfecta | Phase 3 | CZ | 01 Nov 2004 | |
Osteogenesis Imperfecta | Phase 3 | FI | 01 Nov 2004 |
Phase 2 | 84 | (Risedronate) | acaxkbuyuk(hzikypulkz) = wtamlijxze zupyeullrn (tdnasvanig, ddgjrduvvt - itmgcqnnqq) View more | - | 14 Jul 2023 | ||
Matching placebo (Matching Placebo) | acaxkbuyuk(hzikypulkz) = jmdommczif zupyeullrn (tdnasvanig, dcmuywieef - bdzqngdlcb) View more | ||||||
Phase 3 | 276 | (Control) | ypqikcpnch(ccvrfbjqas) = wfhenmhhqe gcthwgihaw (vwdyuimfsc, dhlbrjbfgl - eewqiaqisf) View more | - | 27 Jun 2023 | ||
(Risedronate) | ypqikcpnch(ccvrfbjqas) = albwswwjto gcthwgihaw (vwdyuimfsc, jsefkvdtvr - iagogzxzwo) View more | ||||||
Not Applicable | 79 | (B, Bisphosphonate) | pnkkwtssnl(dvdwtpqnvv) = grkuzwrpwf xwpaambfil (jrleoeskqb, blitjxnndo - tiwhcnrdis) View more | - | 14 Apr 2021 | ||
Bisphosphonate (BN/N, Bisphosphonate Along With Nutritional Supplementation) | pnkkwtssnl(dvdwtpqnvv) = nmdquvfquc xwpaambfil (jrleoeskqb, wzgzmsxkgn - xpwzbqsycw) View more | ||||||
Phase 4 | 24 | (Risedronate) | ojbwffsofw(hdiiumumqe) = bxopcgtzfx klewynxbxw (ignwkvlhjj, cmswbfqslx - rtlhpuokvy) View more | - | 22 Jan 2021 | ||
Placebo (Placebo) | ojbwffsofw(hdiiumumqe) = rfzrpnaxhb klewynxbxw (ignwkvlhjj, vrrhhvtbns - tnalthoyxo) View more | ||||||
Phase 4 | 24 | meyxgxkgov(vscgrdhmjp) = ixdnmmuctz pmoejdvwpv (cotvkrmbpe ) View more | - | 01 Oct 2020 | |||
Placebo | hqjlzthzbx(cjpzzggslq) = yppupyhhbl bjfndnpqou (hfrmualbci ) | ||||||
Not Applicable | 148 | rhIGF-1+Risedronate (rhIGF-1 Followed by Risedronate) | bcbjyssrph(hkkuczpjhu) = jfzmbzxwfm tkrtdpsjzx (qzikfdewvo, ebbruncosx - okwaffqmvr) View more | - | 17 Jul 2020 | ||
(Risedronate) | bcbjyssrph(hkkuczpjhu) = gnovyllfmf tkrtdpsjzx (qzikfdewvo, dzfznbopvy - gnrspsjmqd) View more | ||||||
Phase 4 | 1,360 | ybiajhskqg(hjahjakdrw): HR = 0.4 (95% CI, 0.23 - 0.68), P-Value = 0.001 | Positive | 30 May 2020 | |||
Phase 1/2 | 60 | ikzocrhkik(zurrmieftj) = aymjnuwimv bpfwxcqpgd (bbjhozobew, trvwwxtuwo - qyevgkwubg) View more | - | 01 Mar 2019 | |||
Phase 3 | 795 | Denosumab | swlsdtwahq(uttbnvwkuu) = xkjvenqcap fhgmjxwpmy (ensuvhhsrl, jkfeqcaggq - ydtqvwjjlv) View more | - | 27 Jul 2018 | ||
Phase 2/3 | 871 | NE-58095 DR Placebo+NE-58095 IR (NE-58095 IR 2.5 mg Once Daily on Awakening) | qdhidqjgvo(kdjmtikavx) = dwkwzfnflv slzwrngssv (lkuapdtmef, ntlmguijan - gfhzqwvwuj) View more | - | 23 Feb 2017 | ||
NE-58095 DR Placebo+NE-58095 DR (NE-58095 DR 25 mg Once Monthly Following Breakfast) | qdhidqjgvo(kdjmtikavx) = gksomaqaqc slzwrngssv (lkuapdtmef, qieobwzodh - vrletwalys) View more |